Are you aware that programmed cell death-ligand 1 (PD-L1) testing may not be needed to guide immunotherapy decisions in resectable gastric/gastroesophageal junction (GEJ) cancers?
 
Credit available for this activity expires: 9/22/2026
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002919?ecd=bdc_podcast_libsyn_mscpedu